Fig. 5

The elevated PLPP2 in LUAD served as an independent prognostic risk factor for LUAD. a PLPP2 mRNA levels in paired paracancerous and tumour tissues of patients in cohort 1 were tested by Q-PCR, n = 30. ****P < 0.0001; the student’s t test. b PLPP2 mRNA levels in BEAS-2B cells and LUAD cells were tested by Q-PCR, n = 3. Bars, SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; the student’s t test. c The level of PLPP2 expressions in BEAS-2B cells and LUAD cells were tested by western blot, representative pictures were shown, n = 3. Bars, SD; ***P < 0.001, ****P < 0.0001; the student’s t test. d Representative images of IHC assay detecting levels of PLPP2 expression in paracancerous and tumour tissues of LUAD patients in cohort 2. e–f Statistic analysis of PLPP2 AOD values in paired paracancerous and tumour tissues of stage I LUAD patients in cohort 2, n = 42. Bars, SD; ****P < 0.0001; the student’s t test. g ROC analysis was used to evaluate the diagnostic accuracy of PLPP2 and calculate AUC value of stage I LUAD patients, n = 42. ****P < 0.0001. h 5-year survival probabilities of stage I LUAD patients in high and low PLPP2 groups were evaluated and showed by Kaplan–Meier curves, n = 42. *P < 0.05; Log-rank test. i Multivariate Cox hazard regression analysis of different clinical characters including age, gender and PLPP2 levels, n = 42